 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8788899091929394959697...100101» |
- | letrozole / Generic mfg.
New P4 trial: Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS (clinicaltrials.gov) - Feb 1, 2016
P4, N=100, Completed, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
- | everolimus / Generic mfg.
Enrollment change, Trial primary completion date: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Jan 27, 2016
P3, N=1900, Recruiting, Sponsor: Southwest Oncology Group
N=3500 --> 1900 | Trial primary completion date: Mar 2016 --> Dec 2022
- letrozole / Generic mfg.
Trial primary completion date: Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) (clinicaltrials.gov) - Jan 27, 2016
P3, N=140, Recruiting, Sponsor: Cairo University
N=3500 --> 1900 | Trial primary completion date: Mar 2016 --> Dec 2022 Trial primary completion date: May 2016 --> May 2017
- letrozole / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women (clinicaltrials.gov) - Jan 26, 2016
P4, N=41, Completed, Sponsor: University of Saskatchewan
Trial primary completion date: May 2016 --> May 2017 Recruiting --> Completed | N=80 --> 41 | Initiation date: Jan 2009 --> Jan 2010 | Trial primary completion date: Feb 2011 --> Feb 2012
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment closed: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jan 26, 2016
P1, N=102, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Completed | N=80 --> 41 | Initiation date: Jan 2009 --> Jan 2010 | Trial primary completion date: Feb 2011 --> Feb 2012 Recruiting --> Active, not recruiting
- letrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Metastases: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (clinicaltrials.gov) - Jan 21, 2016
P2, N=60, Active, not recruiting, Sponsor: Xichun Hu
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Jun 2016
- ||| Herceptin (trastuzumab) / Roche
Enrollment closed: PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (clinicaltrials.gov) - Jan 20, 2016
P2, N=151, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Kisqali (ribociclib) / Novartis
New P2 trial: Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer (clinicaltrials.gov) - Jan 19, 2016
P2, N=40, Not yet recruiting, Sponsor: Mayo Clinic
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy, Monotherapy, Metastases: TREnd: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy (clinicaltrials.gov) - Jan 17, 2016
P2, N=100, Recruiting, Sponsor: Fondazione Sandro Pitigliani
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Jun 2016
- || Trial primary completion date: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (clinicaltrials.gov) - Jan 17, 2016
P2, N=299, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Oct 2015 --> Jun 2016 Trial primary completion date: Sep 2015 --> Sep 2018
- letrozole / Generic mfg.
Trial completion: Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=95, Completed, Sponsor: Istanbul University
Trial primary completion date: Sep 2015 --> Sep 2018 Active, not recruiting --> Completed
- letrozole / Generic mfg., menotropin / Generic mfg.
Trial completion: Comparison of Treatment Modalities in Poor Responders Undergoing IVF (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=80, Completed, Sponsor: Ercan Bastu
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Phase classification, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 7, 2016
P4, N=73, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Phase classification: P2 --> P4
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jan 7, 2016
P2, N=56, Not yet recruiting, Sponsor: City of Hope Medical Center
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
New trial: A Comparison of Letrozole and Clomifene Citrate (clinicaltrials.gov) - Jan 6, 2016
P=N/A, N=40, Recruiting, Sponsor: The University of Hong Kong
- ||| letrozole / Generic mfg.
New trial: GLC: Graceful Lifestyle Changes Study for PCOS and Infertility (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=240, Not yet recruiting, Sponsor: University of British Columbia
- letrozole / Generic mfg.
Trial primary completion date, Surgery: Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=200, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Phase classification: P2 --> P4 Trial primary completion date: Mar 2016 --> Mar 2017
- ||||| New P2 trial, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Dec 10, 2015
P2, N=200, Not yet recruiting, Sponsor: Haukeland University Hospital
- Enrollment open, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Dec 9, 2015
P2, N=59, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Mar 2016 --> Mar 2017 Active, not recruiting --> Recruiting
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: COOL-COS: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (clinicaltrials.gov) - Dec 4, 2015
P4, N=28, Completed, Sponsor: University of Sao Paulo
Active, not recruiting --> Recruiting Enrolling by invitation --> Completed | N=40 --> 28 | Trial primary completion date: Oct 2015 --> Mar 2015
- Elonva (corifollitropin alfa) / Organon
Trial primary completion date: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study (clinicaltrials.gov) - Dec 3, 2015
P1, N=40, Enrolling by invitation, Sponsor: University of Sao Paulo
Enrolling by invitation --> Completed | N=40 --> 28 | Trial primary completion date: Oct 2015 --> Mar 2015 Trial primary completion date: Jul 2015 --> Jan 2016
- letrozole / Generic mfg., nintedanib / Generic mfg.
New P1 trial: Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics (clinicaltrials.gov) - Dec 2, 2015
P1, N=22, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
- sapanisertib (CB-228) / Calithera
New P1 trial: Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer (clinicaltrials.gov) - Dec 2, 2015
P1, N=13, Not yet recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- | Enrollment closed: HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. (clinicaltrials.gov) - Nov 30, 2015
P3, N=1050, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Trial primary completion date: Jul 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. (clinicaltrials.gov) - Nov 27, 2015
P3, N=1050, Recruiting, Sponsor: National Cancer Institute, Naples
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Mar 2016
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Nov 17, 2015
P3, N=666, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Aug 2019
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Phase classification, Enrollment change, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Nov 16, 2015
P1, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Aug 2019 Phase classification: P1/2 --> P1 | N=300 --> 200
- | Ibrance (palbociclib) / Pfizer
New P2 trial: PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) - Nov 14, 2015
P2, N=200, Not yet recruiting, Sponsor: Thomas Hatschek
- || letrozole / Generic mfg.
Trial primary completion date: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (clinicaltrials.gov) - Nov 10, 2015
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1/2 --> P1 | N=300 --> 200 Trial primary completion date: Dec 2016 --> Dec 2017
- |||| letrozole / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Study of Breast Cancer Prevention by Letrozole in High Risk Women (clinicaltrials.gov) - Nov 10, 2015
P2, N=55, Completed, Sponsor: Carol Fabian, MD
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=108 --> 55 | Trial primary completion date: Jul 2015 --> Mar 2015
- || letrozole / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Metastases: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=54, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed | N=108 --> 55 | Trial primary completion date: Jul 2015 --> Mar 2015 Trial primary completion date: Dec 2015 --> May 2016
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial, Combination therapy, Metastases: Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate (clinicaltrials.gov) - Nov 9, 2015
P3, N=130, Not yet recruiting, Sponsor: Pfizer
- imatinib / Generic mfg., letrozole / Generic mfg.
Trial primary completion date: Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 23, 2015
P2, N=45, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> May 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- ||||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
New P2 trial, Metastases: CHEOPS: Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (clinicaltrials.gov) - Oct 23, 2015
P2, N=130, Not yet recruiting, Sponsor: ARCAGY/ GINECO GROUP
- letrozole / Generic mfg., cyclophosphamide / Generic mfg.
New trial: Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=200, Recruiting, Sponsor: Capital Medical University
- ||||| Verzenio (abemaciclib) / Eli Lilly
Enrollment closed: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Oct 21, 2015
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Oct 2016 --> Oct 2017 Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Enrollment closed, Trial primary completion date: Aromatase Inhibitor Host Factors Study (clinicaltrials.gov) - Oct 20, 2015
P=N/A, N=140, Active, not recruiting, Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jun 2015
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Oct 14, 2015
P2, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jun 2015 Recruiting --> Active, not recruiting
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Oct 7, 2015
P2, N=112, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2021 --> Jun 2018
- Kisqali (ribociclib) / Novartis, buparlisib (AN2025) / Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: LeeBLet: Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (clinicaltrials.gov) - Oct 7, 2015
P1, N=13, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2021 --> Jun 2018 Trial primary completion date: Nov 2016 --> Dec 2015
- letrozole / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) - Oct 7, 2015
P2, N=3, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Nov 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> May 2010
- |||| Trial primary completion date: MINDACT: Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (clinicaltrials.gov) - Oct 6, 2015
P3, N=6600, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> May 2010 Trial primary completion date: Mar 2015 --> Oct 2015
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Sep 29, 2015
P2, N=40, Not yet recruiting, Sponsor: National University Hospital, Singapore
- | letrozole / Generic mfg.
Trial completion, Enrollment change: Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion (clinicaltrials.gov) - Sep 29, 2015
P2/3, N=423, Completed, Sponsor: Ain Shams University
Trial primary completion date: Mar 2015 --> Oct 2015 Recruiting --> Completed | N=320 --> 423
- letrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Metastases: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=60, Active, not recruiting, Sponsor: Xichun Hu
Recruiting --> Completed | N=320 --> 423 Trial primary completion date: Jun 2015 --> Dec 2015
- letrozole / Generic mfg.
Trial primary completion date: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Sep 24, 2015
P2, N=115, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Jun 2020 --> Jun 2017
- Ibrance (palbociclib) / Pfizer
Enrollment open, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Sep 22, 2015
P1, N=25, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jun 2020 --> Jun 2017 Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy, Monotherapy, Metastases: TREnd: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy (clinicaltrials.gov) - Sep 16, 2015
P2, N=100, Recruiting, Sponsor: Fondazione Sandro Pitigliani
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
New P2 trial: LVCCFOROI: Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS ) (clinicaltrials.gov) - Sep 16, 2015
P2, N=110, Not yet recruiting, Sponsor: mostafa gomaa hamid halawa
- |||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Sep 2, 2015
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021